Latigo Biotherapeutics

Latigo Biotherapeutics (Ticker: LTGO US) develops non-opioid treatments for short-term and long-term pain. Its medicines are designed to block pain signals in the body without acting on the brain, an approach the company profile said may reduce addiction risks linked to opioid painkillers. Its lead candidate, LTG-001, is being developed for moderate to severe acute pain, including pain after surgery; Phase 3 testing was expected to begin in the second half of 2026. LTG-321 is being tested for chronic pain caused by conditions such as knee osteoarthritis. Founded in 2018, the company had not yet generated product revenue at the time of the profile.

The scheduled listing date on Nasdaq was August 7, 2026. The proposed offering comprises 16,000,000 shares at an indicative price range of $16.00–18.00 per share. At the indicative range midpoint, the base offering would represent $272.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is around $1.00 billion.

Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities are managing the offering.